Navigation Links
Genetics May Determine Antidepressants' Effectiveness
Date:1/23/2008

German researchers identify 11 variants that seem to influence outcome

WEDNESDAY, Jan. 23 (HealthDay News) -- Genetic variations that predict patient response to the two common antidepressant drugs citalopram (brand name Celexa) and venlafaxine (Effexor) have been identified by German researchers.

The team at the Max Planck Institute of Psychiatry in Munich found that 11 variants in the gene for a protective transporter protein called P-gp, which removes drugs and other substances from the brain, compromise the effectiveness of these two drugs.

In the first part of the study, the researchers knocked out genes for P-gp in mice and gave them antidepressants. They found that brain concentrations of citalopram and venlafaxine were regulated by P-gp, indicating that the antidepressants were "substrates" of the transporter protein.

Next, the team analyzed 443 people on antidepressants for genetic variants that correlated with reduced efficacy of the two antidepressants.

"To our knowledge, our results provide for the first time evidence that genetic variants in the (gene for P-gp) account for differences in the clinical efficacy of antidepressants, most likely by influencing their access to the brain," the researchers wrote.

The findings, published in the Jan. 24 issue of the journal Neuron, suggest that genetic testing could help predict how individual patients would react to specific antidepressants, the researchers said.

They added that genetic tests may also help predict the effectiveness of any drugs used to treat neurological diseases.

"The general conclusion to be drawn is that any drug treatment administered to treat CNS (central nervous system) diseases should be analyzed for its P-gp substrate status, which can be determined by using knockout mice. From a clinical point of view, the findings warrant that patients receiving a drug that is a P-gp substrate for the treatment of brain diseases are genotyped to exclude the possibility that a patient receives a drug that fails to enter the CNS to an extent required for efficacy," the study authors wrote.

Future development of antidepressants should take into account whether new drugs are transported by P-gp, and clinical trials of antidepressant drugs need to factor in the P-gp genetic status of participants, the researchers recommended.

More information

The U.S. National Institute of Mental Health has more about depression.



-- Robert Preidt



SOURCE: Cell Press, news release, Jan. 23, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetics Influence Blood Pressure Medications
2. People with anorexia less likely to be blamed when biology, genetics explained
3. Top10 research advances include studies on genetics and stem cell research, stents
4. Heart attack risk from smoking due to genetics
5. Genetics May Boost Mexican-Americans Risk for Alcoholism
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
7. Researchers develop powerful tool to study the genetics of inflammation
8. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
10. Genetics and Risk, This Week on Your Cancer Today(TM)
11. CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetics May Determine Antidepressants' Effectiveness
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: